The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.

This trial will follow approximately 200 patients with HER2 negative (HER2- low or HER2-0)- (IHC<2+) MBC who are starting T-DXd. The study will test a newly developed test to measure HER2 protein on tumor cells using an antibody that 'lights up' when attached to HER2. The 'light' is called fluorescence. Cells with HER2 light up when viewed under a microscope with a special light. The fluorescence strength matches with the amount of HER2 protein on the breast cancer cell. We propose to prove this test works in patients with MBC that is HER2 low (IHC<2+) and who are beginning treatment with T-DXd. Each patient in this study will have their tumor tested using this new fluorescence test (Quantitative Immunofluorescence, or QIF). Patients will be followed for response to T-DXd. We will compare the QIF score with IHC score as they relate to patients who benefit from T-DXd.

To determine the anti-proliferative effect of tirzepatide on the endometrium of endometrial cancer (EC) patients .

Have you been diagnosed with Molecular Low-Risk Early-Stage Breast Cancer? If so, you may be able to take part in a research study using lower dose of tamoxifen, to evaluate if it is a better treatment than usual hormonal therapy in women with low-risk, early-stage breast cancer.

The purpose of this study is to estimate the probability of participants being off all anti-cancer treatment (with the exception of endocrine therapy for those with ER+ disease) and free of disease progression 4 years from study entry.

Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.

The purpose of this study is to test the safety and eff ectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan; or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating your type of cancer. Additional information collected from this study may also help inform the future use of these drugs.

Do you have metastatic or incurable, recurrent head and neck cancer? If so, you may be able to participate in a research study to find out if a new investigational drug, in combination with pembrolizumab, can help people with advanced head and neck cancer.

In this study, we want to find out if a medicine called Olaparib works as well as the usual treatment for ovarian cancer. We also want to see if this medicine can help stop the cancer from growing or coming back.

This research is being done in participants who have Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer, to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab). Toripalimab and bevacizumab have been approved by the Food and Drug Administration (FDA) to treat other cancers, but not Liver cancer. Casdozokitug has not been approved by the FDA to treat any cancers.